Sistema de Salut de Catalunya
[Giner-Soriano M, Ouchi D] Fundació Institut Universitari Per a la Recerca a l’Atenció Primària De Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Prat-Vallverdú] Marketing Farmacéutico and Investigación Clínica, Barcelona, Spain. [Vilaplana-Carnerero C] Fundació Institut Universitari Per a la Recerca a l’Atenció Primària De Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Plataforma SCReN, UIC IDIAPJGol, Barcelona, Spain. [Morros R] Fundació Institut Universitari Per a la Recerca a l’Atenció Primària De Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Plataforma SCReN, UIC IDIAPJGol, Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Institut Català de la Salut, Barcelona, Spain
IDIAP Jordi Gol
2023-02-07T11:35:46Z
2023-02-07T11:35:46Z
2023-02-07
Oral anticoagulants; Atrial fibrillation; Gender differences
Anticoagulants orals; Fibril·lació auricular; Diferències de gènere
Anticoagulantes orales; Fibrilación auricular; Diferencias de género
Objectives: To describe the sex and gender differences in the treatment initiation and in the socio-demographic and clinical characteristics of all patients initiating an oral anticoagulant (OAC), and the sex and gender differences in prescribed doses and adherence and persistence to the treatment of those receiving direct oral anticoagulants (DOAC). Material and methods: Cohort study including patients with non-valvular atrial fibrillation (NVAF) who initiated OAC in 2011–2020. Data proceed from SIDIAP, Information System for Research in Primary Care, in Catalonia, Spain. Results: 123,250 people initiated OAC, 46.9% women and 53.1% men. Women were older and the clinical characteristics differed between genders. Women had higher risk of stroke than men at baseline, were more frequently underdosed with DOAC and discontinued the DOAC less frequently than men. Conclusion: We described the dose adequacy of patients receiving DOAC, finding a high frequency of underdosing, and significantly higher in women in comparison with men. Adherence was generally high, only with higher levels in women for rivaroxaban. Persistence during the first year of treatment was also high in general, being significantly more persistent women than men in the case of dabigatran and edoxaban. Dose inadequacy, lack of adherence and of persistence can result in less effective and safe treatments. It is necessary to conduct studies analysing sex and gender differences in health and disease.
Article
Published version
English
Anticoagulants (Medicina); Fibril·lació auricular - Tractament - Diferències entre sexes; Atenció primària - Catalunya; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::Anticoagulants; DISEASES::Cardiovascular Diseases::Heart Diseases::Arrhythmias, Cardiac::Atrial Fibrillation; Other subheadings::Other subheadings::Other subheadings::/drug therapy; HEALTH CARE::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care; Catalonia; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos hematológicos::anticoagulantes; ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::arritmias cardíacas::fibrilación atrial; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; ATENCIÓN DE SALUD::administración de los servicios de salud::gestión de la atención al paciente::atención integral de salud::atención primaria de la salud; Cataluña
Frontiers Media
Frontiers in Pharmacology;14
https://doi.org/10.3389/fphar.2023.1110036
Data were obtained by request of the Pharmacotherapeutic Harmonization Program of the Catalan Health Service.
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
